Carolyn Vachani RN, MSN, AOCN
Last Modified: November 18, 2006
This analysis was done on a study designed to look at the benefit of chemotherapy for early stage lung cancers. The researchers have analyzed the use of radiation therapy in the patients enrolled on this study. The patients were randomized to receive chemotherapy or not, so some patients received radiation and chemotherapy, some chemotherapy alone or radiation alone.
The analysis found that patients who had no cancer detected in the lymph nodes (N0), had worse 5-year survival when they received radiation therapy, regardless of whether or not they also received chemotherapy. This is not surprising, as these patients have the lowest risk of local nodal recurrence, and thus stand to gain the least benefit from local treatment. For patients with N1 nodal involvement, on the other hand, radiation alone improved 5-year survival, although the combination of radiation and chemotherapy resulted in a worse survival. Finally, patients with N2 nodal involvement have improved 5-year survival in both the radiation alone and combination therapy groups.
Caution must be used in interpreting these results because patients were not randomized to receive radiation or not. A randomized study is ongoing to better evaluate the use of radiation therapy in early stage lung cancers.
Jul 7, 2011 - Erlotinib is superior to chemotherapy for improving progression free survival in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations, with acceptable toxicity, according to a study presented at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer and held from July 3 to 7 in Amsterdam, Netherlands.
Jul 7, 2011
Oct 31, 2014
May 25, 2010
Oct 31, 2014